JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 166 filers reported holding JUNO THERAPEUTICS INC in Q4 2016. The put-call ratio across all filers is 1.25 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $8,428,000 | -13.3% | 184,194 | -15.0% | 0.00% | -20.0% |
| Q3 2017 | $9,723,000 | -13.2% | 216,742 | -42.1% | 0.01% | -16.7% |
| Q2 2017 | $11,198,000 | +7.2% | 374,610 | -20.4% | 0.01% | +20.0% |
| Q1 2017 | $10,446,000 | +54.4% | 470,741 | +31.1% | 0.01% | +25.0% |
| Q4 2016 | $6,766,000 | -54.0% | 358,995 | -6.3% | 0.00% | -55.6% |
| Q2 2016 | $14,724,000 | -23.0% | 383,023 | -23.7% | 0.01% | -18.2% |
| Q1 2016 | $19,130,000 | +344.9% | 502,214 | +375.2% | 0.01% | +266.7% |
| Q3 2015 | $4,300,000 | -25.7% | 105,680 | -2.6% | 0.00% | 0.0% |
| Q2 2015 | $5,784,000 | -36.5% | 108,467 | -27.7% | 0.00% | -40.0% |
| Q1 2015 | $9,103,000 | -75.1% | 150,035 | -78.6% | 0.01% | -76.2% |
| Q4 2014 | $36,549,000 | – | 700,001 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |